The Influencer Lilly Gaddis has claimed that her YouTube channel has been demonetized for being “too pro-White.” Gaddis, who has a following of over 240,000 on X and over 60,000 on Instagram, ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...

Len Yaffee says Eli Lilly stock will find it hard to push any higher from here. The Kassef Capital's chief executive explained why in a recent CNBC interview. LLY shares are already up a whopping 75% ...

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue. The stock recently ...

Eli Lilly & Co.’s stock has reached new highs in recent days, becoming the first pharmaceutical company to hit a $1 trillion valuation. The surge has also lifted the founding family’s private ...

A fresh call from Bernstein has Wall Street doing a double-take. Bernstein just reset Eli Lilly’s price target. Analyst Breen cites talks about GLP-1 catalysts, robust U.S. policy, and promising ...

Philadelphia is about to become the host of the fifth Lilly Gateway Labs, a biotech incubator for early-stage companies backed by Eli Lilly & Co., writes Harold Brubaker for The Philadelphia Inquirer.

Previous mega blockbusters took years to reach their peak sales. Lilly’s tirzepatide franchise is on course to exceed them just a few years in. Eli Lilly is rewriting the rules of pharma. Not only did ...

Eli Lilly’s stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement ...

Eli Lilly is upgraded to a "Strong Buy" due to 54% revenue growth, driven by Zepbound and Mounjaro's success in obesity and T2D. The company is expanding its pipeline with Orforglipron [oral GLP-1 ...